The 340B drug pricing program could change in a way that would directly impact your organization’s cash flow and financial reporting. The pilot program shifts from upfront discounts to a rebate model for certain high-cost drugs. For CFOs and controllers at nonprofit and Tribal health systems and health clinics, understanding these changes now is critical to maintaining financial stability and audit readiness.
⚖️ COURT UPDATE (December 29, 2025)
U.S. District Judge Lance Walker granted a temporary restraining order blocking the 340B Rebate Model Pilot nationwide. The pilot will NOT launch on January 1, 2026 as planned.
What this means: The January 1 implementation is halted—for now. However, this is a temporary order, and the legal case continues. CFOs and controllers should still understand the financial impacts described below, as the pilot could be implemented later pending court rulings.
Bottom line: Use this delay to prepare. Contact Chris Tyhurst to discuss readiness strategies.
What’s Changing: From Direct Discounts to a Rebate Model
If you’re managing finances at a nonprofit or Tribal health system or clinic, the pilot would bring a significant change to your 340B drug program operations. Here’s what’s happening and why it matters to your bottom line.
This change affects how some nonprofit and Tribal health systems and clinics acquire certain high-cost outpatient drugs under the federal 340B program. Historically, eligible safety net providers could purchase discounted drugs at the point of sale, applying the savings immediately to their cash flow and operations. Under a newly approved pilot program involving eight major pharmaceutical companies and nine widely used drugs (including Eliquis, Stelara, and Xarelto), 340B entities will need to purchase these drugs at the full list price, then apply to receive a rebate after dispensing them to eligible patients.
How the New Process Works
01
Pay Full Price Upfront
Covered entities will pay the wholesale acquisition cost (WAC) up front for the selected drugs.
02
Submit Claims Data
After dispensing, providers submit required claims data to the drug manufacturer using a specified IT platform.
03
Manufacturer Review
The manufacturer reviews the submission and, if the provider’s use aligns with 340B eligibility, remits a rebate—typically representing the difference between the WAC and the 340B ceiling price—back to the provider, generally within 10 days.
This pilot is scheduled to run for at least one year, with the federal Health Resources and Services Administration (HRSA) evaluating its effectiveness for broader adoption.
How Will This Impact Your Health System’s Finances and Operations?
Let’s be direct: this isn’t just a process change. For many health systems and clinics, this shift will create real financial pressure. Several critical impacts deserve special attention:
Cash Flow
Strain
Instead of benefiting from immediate cost reductions via upfront discounts, health systems and clinics will have to float the full drug cost until manufacturers process and remit rebates.
Depending on volume and drug mix, this could tie up millions of dollars in working capital previously used to support patient care, investments in facilities, or other mission-critical needs.
Administrative Burden
Health systems and clinics must build or adapt systems and processes to collect, validate, and transmit claims-level data for affected medications.
Staff may need to be reassigned or hired to manage submissions, track rebates, reconcile expected versus actual payments, and resolve disputes.
Financial Statement Considerations
The timing change in cost recognition and rebate receipt could affect how expenses and revenues are recorded for both internal management and annual audits.
There may be lag between drug purchase (expense incurred) and rebate realization (income received), impacting reported margins—especially for health systems and clinics experiencing large 340B volumes.
Other
Headwinds
This pilot arrives as many safety net providers face looming or enacted cuts to Medicaid reimbursement, potential Medicare payment reductions, and continued pressure from uncompensated care obligations.
Any delay in cash flow or uncertainty in recognizing 340B-related savings will be felt acutely.
What Are the Audit and Compliance Implications?
Here’s what this means for your financial reporting and audits:
Revenue Recognition and Cutoff: It is essential to evaluate how and when rebates should be recognized as income. Should your organization record rebate income at the time the rebate application is submitted, or upon confirmation of receipt? Accounting guidance generally points to when collection is probable and amount is determinable.
Allowance for Rebates Not Yet Received: With new risks (rejected or delayed rebates, data errors), some entities may need to book an allowance for rebates expected but not received at year-end, analogous to allowance accounts for doubtful receivables.
Internal Controls: Adequate segregation of duties, accuracy checks on submitted claims data, and robust monitoring of rebate payments will be required to validate balances reported in financial statements and to pass audit scrutiny.
Documentation and Audit Trail: Finance teams must ensure clear, auditable records tracking every rebate-eligible transaction from acquisition through rebate receipt. This includes correspondence with manufacturers, proof of timely submissions, and explanation of any denied or partial rebates.
System Readiness: ERP and pharmacy systems may not be configured for this “pay now, get paid later” structure. Early coordination with IT and pharmacy operations is crucial.
Key Questions for Finance Leaders and Audit Committees
How significant is the expected cash flow impact from buying at WAC before rebate receipt?
Does our current pharmacy and financial system fully support tracking of rebate-eligible purchases, submissions, and receipts, with reconciling capability?
What is our process for resolving denied or delayed rebates, and how is this accounted for in our financial statements?
Who has ownership over monitoring compliance with 340B eligibility, and what steps are taken to prevent inadvertent submission errors?
Are changes to internal controls, documentation, or financial reporting policies needed to accurately reflect 340B rebate activity?
Have we consulted with legal counsel or 340B program experts to ensure we remain compliant with both federal program requirements and generally accepted accounting principles?
How to Prepare
Model the Impact
Work with pharmacy, supply chain, and finance to estimate the anticipated monthly outlay for affected drugs (WAC price), expected rebate cycle times, and potential cash flow gaps.
Assess and Bolster Systems
Review whether your financial and pharmacy systems can track rebate-eligible transactions, submit timely and error-free claims, monitor in-transit rebates, and document everything in a manner suitable for audit.
Update Internal Controls and Policies
Revise applicable procedures to ensure accurate, timely reporting and reconciliation. Define roles and responsibilities for data submission and rebate monitoring. Document significant processes and internal controls for the audit file.
Educate Key Staff
Train those responsible for pharmacy purchasing, supply chain, and finance on new workflows, submission requirements, and the importance of timely reporting.
Plan for Financial Statement Disclosure
Discuss with your auditor how you will account for rebate-related receivables and any allowances, as well as appropriate note disclosures for stakeholders and boards.
Engage with Industry Updates
Maintain contact with HRSA and peer institutions to stay abreast of any developments or common issues as the pilot launches. Consider consulting with a 340B specialist or legal advisor for guidance outside of financial reporting scope.
Conclusion
While the 340B rebate pilot initially affects only a limited number of drugs, it signals possible long-term change for the entire program. Advanced preparation on the finance and audit front will help you mitigate cash flow disruption, safeguard program compliance, and position your organization for success in this evolving environment.
Questions?
If you have questions about financial reporting, 340B compliance, internal controls, or audit preparation in light of 340B changes, connect with our team for support tailored to your organization’s needs.
Our healthcare advisory team has extensive experience helping nonprofit and Tribal healthcare organizations navigate complex regulatory and financial reporting challenges.
Note: This article is not legal, accounting, or tax advice or a substitute for consulting 340B program experts. For program-specific compliance questions, please seek guidance from your legal or healthcare consultants.
About the Authors
Christopher Tyhurst, CPA, is a Principal at REDW Advisors & CPAs and serves as Quality Management Director of the Audit & Assurance practice. With extensive experience auditing nonprofit and Tribal healthcare organizations, Chris specializes in healthcare financial audits and consulting, with particular expertise in hospitals, health centers, patient accounts receivable, and internal controls. He is a past President of the New Mexico chapter of the Healthcare Financial Management Association (HFMA) and regularly presents on healthcare accounting, financial reporting, and internal control matters.
Aaron B. Starr, CPA, MHA, MBA, is a Principal at Starr & Leaf CPA Group PLLC. He has experience in healthcare finance and operations. Previously, Aaron held positions as a Director of Finance and Chief Financial Officer in the healthcare industry. He brings a broad range of experience and management skills to Starr & Leaf in his work in general taxation, business advisory and firm operations. He holds a Bachelor of Science in cellular and molecular biology from the University of Washington, a Master of Business Administration from Western Washington University, a Certificate in Accounting from the University of Washington’s Foster School of Business and a Master of Health Administration from the University of Washington’s School of Public Health.
